Results 91 to 100 of about 17,785 (168)

Multicentre Evaluation of an AI‐Assisted Urine Test for Clinically Significant Prostate Cancer in Men Undergoing Initial Biopsy

Journal of Extracellular Vesicles, Volume 15, Issue 4, April 2026.
ABSTRACT The Extracellular Vesicles Gene‐based Prostate Score (EGPS), powered by DeepSeek, is an artificial intelligence (AI) diagnostic tool that enhances the detection of clinically significant prostate cancer (csPCa) using urinary EV‐derived gene expression, without requiring digital rectal examination (DRE).
Shaoqin Jiang, Chunguang Yang, Zhangcheng Huang, Zebang Guo, Feiting Lu, Xinwen Nian, Zhenlin Chen, Pengwei Luo, Jiawei Jiang, Xu Gao, Mengqiang Li, Fei Liu   +11 more
wiley   +1 more source

In vivo stable 211At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure

EJNMMI Radiopharmacy and Chemistry
Background Prostate cancer is a common cancer among men worldwide that has a very poor prognosis, especially when it progresses to metastatic castration-resistant prostate cancer (mCRPC).
Hiroyuki Suzuki, Kento Kannaka, Mizuki Hirayama, Tomoki Yamashita, Yuta Kaizuka, Ryota Kobayashi, Takahiro Yasuda, Kazuhiro Takahashi, Tomoya Uehara   +8 more
doaj   +1 more source

Diagnostic Value of Rapid On‐Site Evaluation Combined With Prostate Biopsy in Prostate Cancer

The Prostate, Volume 86, Issue 5, Page 542-549, April 2026.
ABSTRACT Objective To investigate the application value of Rapid On‐Site Evaluation (ROSE) in prostate biopsy. Methods All consecutive subjects who attended our clinic to underwent magnetic resonance imaging (MRI)‐ultrasound fusion biopsy due to highly suspicious findings on MRI for prostate cancer (PCa) and met the inclusion criteria were enrolled ...
Hong Ma, Anzi Cao, Huiming Hou, Pengjie Wu, Ben Wan, Ming Liu   +5 more
wiley   +1 more source

Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases

Scientific Reports
Prostate-specific membrane antigen (PSMA)-targeted theranostics have profoundly reshaped prostate cancer (PCa) management. However, patterns of PSMA expression heterogeneity and the identification of alternative targets for PSMA-negative cases remain ...
Yelin Mulati, Qi Shen, Yuxuan Tian, Yuke Chen, Kaifeng Yao, Wei Yu, Yunpeng Cui, Xuedong Shi, Zhisong He, Qian Zhang, Yu Fan   +10 more
doaj   +1 more source

Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 199-206, April 2026.
ABSTRACT Objective 177Lu‐PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration‐resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177Lu‐PSMA‐RLT from two university ...
Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon‐iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee   +6 more
wiley   +1 more source

Prostate‐specific membrane antigen (PSMA)‐PET‐avid prostate cancers show stronger PSMA immunohistochemistry staining on biopsy cores

BJU International, EarlyView.
Jonathon Carll, Henry Yen‐Cheng Pan, Nathan Lawrentschuk, Andrew Ryan   +3 more
wiley   +1 more source

Diagnostic accuracy and outcomes of lymph node staging in intermediate‐risk prostate cancer

BJU International, Volume 137, Issue 4, Page 667-676, April 2026.
Objective To evaluate the diagnostic performance of different staging modalities and oncological outcomes in patients with intermediate‐risk (IR) prostate cancer (PCa) undergoing radical prostatectomy (RP) with pelvic lymph node dissection (PLND).
Christopher Kniep, Tobias Maurer, Ben Frederik Hartwieg, Philipp Mandel, Mike Wenzel, Fabian Falkenbach, Kristian Krpina, Lars Budäus, Alexander Haese, Georg Salomon, Thomas Steuber, Markus Graefen, Derya Tilki, Felix Preisser   +13 more
wiley   +1 more source

Self‐Immolative Systems in Diagnostic and Therapeutic Applications

ChemMedChem, Volume 21, Issue 5, 13 March 2026.
Self‐Immolative Systems enable the precise, residue‐free release of active molecules, drugs, probes, or sensors, via cyclization or elimination, triggered by specific stimuli. Their versatility drives advances in drug delivery, diagnostics, nanotechnology, materials chemistry, and biosensing, offering chemists control over molecular activation and ...
Windbedema Prisca Ouédraogo, Thomas Cailly, Valérie Collot   +2 more
wiley   +1 more source

68Ga-labeled prostate specific membrane antigen HBED-CC PET/MRI for staging and evaluating the clinicopathological characteristics in newly diagnosed prostate cancer

European Journal of Medical Research
Objective The purpose of this study was to investigate the role of 68Ga-labeled prostate specific membrane antigen HBED-CC (68Ga-PSMA-11) PET/MRI in primary staging and to evaluate the relationship between PSMA-derived parameters and clinicopathological ...
Xiaoyu Su, Shuangli Yang, Feng Qiao, Hui Wang, Tao Wu, Gan Zhu, Wenjing Yu, Xiao Wang   +7 more
doaj   +1 more source

Prostate‑specific membrane antigen: Molecular functions and emerging roles as a therapeutic target (Review). [PDF]

Mol Med Rep
Watanabe R, Sakaue T, Miura N, Kikugawa T, Saika T.   +4 more
europepmc   +1 more source